Nord/LB Reiterates “Neutral” Rating for Novartis (NVS)

Nord/LB reissued their neutral rating on shares of Novartis (NYSE:NVS) in a research note released on Wednesday, December 27th.

Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. reiterated a neutral rating on shares of Novartis in a report on Tuesday, October 24th. Bank of America downgraded Novartis from a neutral rating to an underperform rating in a report on Wednesday, December 6th. Leerink Swann increased their price objective on Novartis from $89.00 to $91.00 and gave the company a market perform rating in a report on Monday, October 23rd. Finally, Zacks Investment Research downgraded Novartis from a buy rating to a hold rating in a report on Friday, October 6th. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $85.32.

Shares of Novartis (NYSE NVS) opened at $85.67 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81. The stock has a market capitalization of $222,550.00, a PE ratio of 30.49, a price-to-earnings-growth ratio of 2.55 and a beta of 0.74. Novartis has a 12-month low of $69.53 and a 12-month high of $86.90.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.04. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The company had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. During the same quarter last year, the company earned $1.23 EPS. Novartis’s revenue for the quarter was up 2.4% compared to the same quarter last year. equities research analysts expect that Novartis will post 4.77 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in NVS. Geode Capital Management LLC lifted its position in Novartis by 19.8% during the 1st quarter. Geode Capital Management LLC now owns 18,918 shares of the company’s stock worth $1,405,000 after acquiring an additional 3,125 shares during the period. Beach Investment Management LLC. acquired a new stake in Novartis during the 2nd quarter worth approximately $5,592,000. Blair William & Co. IL lifted its position in Novartis by 18.5% during the 2nd quarter. Blair William & Co. IL now owns 177,392 shares of the company’s stock worth $14,807,000 after acquiring an additional 27,743 shares during the period. Marshall Wace North America L.P. lifted its position in Novartis by 39.0% during the 2nd quarter. Marshall Wace North America L.P. now owns 964,946 shares of the company’s stock worth $80,091,000 after acquiring an additional 270,799 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Novartis during the 2nd quarter worth approximately $1,259,000. Hedge funds and other institutional investors own 10.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/12/novartis-nvs-neutral-rating-reaffirmed-at-nordlb.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply